Inclusion Criteria:  ≥ 18 years of age at the time of enrollment Signs and symptoms of chest pain that prompted further evaluation by either a heart angiogram or a scan of the heart (coronary CT angiogram) within the previous 5 years Willing to provide written informed consent Non-obstructive CAD defined as 0 to 49% diameter reduction of a major epicardial vessel or a FFR>0.80 Completed CRT within the last 7 days (with the exception of the 10 patients enrolled in the data development set)  Exclusion Criteria:  Patients unable to fit into device Non-ambulatory patients Patients who meet device contraindications Patients with claustrophobia or unable to lie supine for 5 minutes Prisoners History of noncompliance (with medical therapy, protocol, or follow-up) History of non-ischemic dilated or hypertrophic cardiomyopathy Documented acute coronary syndrome (ACS) within previous 30 days Left ventricular ejection fraction (LVEF) <40%, New York Heart Association heart failure (NYHA HF) class III-IV, or hospitalization for Reduced ejection fraction (HFrEF) within 180 days Stroke within previous 180 days or intracranial hemorrhage at any time End-stage renal disease, on dialysis, or estimated glomerular filtration rate (eGFR) <30 ml/min. Severe valvular disease or likely to require surgery/Transcatheter aortic valve replacement (TVAR) within 3 years Life expectancy <3-yrs. due to non-cardiovascular comorbidity Enrolled in a competing clinical trial Prior intolerance to both an ACE-I and ARB If intolerant to a statin unless taking a PCSK9 as a statin replacement by their clinical provider Pregnancy